Recombinant adenoviruses have enormous potential as system the efficiency of viral infection was markedly vectors for gene therapy. They have evolved an efficient enhanced and was targeted to the EGFR. The adenobodymethod of infection and a wide host range but this leads directed infection correlated with the level of EGF receptor to concerns about the specificity of gene delivery. In order expressed on the cells and could be blocked by competo target an adenovirus type 5-based vector we have investition with pure EGF. Peptide inhibition experiments sugtigated an antibody approach. A virus neutralising scFv gest that infection is mediated directly through attachment antibody fragment was isolated from a phage library and a to the EGFR and does not require penton-integrin inter-C-terminal fusion protein with epidermal growth factor actions. This work shows that the 'adenobody' approach (EGF) constructed. This fusion protein, or 'adenobody', can enhance the efficiency as well as target adenoviral bound both to the fibre protein of the adenovirus and to the infection and has numerous potential applications for EGF receptor (EGFR) on human cells, and was able to gene therapy. direct adenoviral binding to the new receptor. Using this
Introduction event from internalisation. Human adenoviruses have been widely used as vectors
The cell surface fibre receptor is widespread so the for delivery of foreign genes to mammalian cells. [1] [2] [3] [4] A adenovirus is capable of infecting a wide variety of cell number of properties of the adenovirus (Ad) system types. This broad range of infection needs to be restricted make it a good candidate for gene therapy. The viruses in order to exploit the full potential of adenoviral vectors can stably incorporate relatively large insertions of for gene therapy. Since the penton base-integrin interacforeign DNA into their genome, they can be concentrated tion is necessary for the internalisation of the adenoto high titres from infected cells and they have a highly virus, 7 we hypothesised that blocking the normal fibre efficient mode of infection which does not require host binding and allowing viral interaction with an alternative cell replication. 1, 3 Adenovirus infection is initiated by the receptor would not interfere with subsequent viral infechigh affinity binding of the fibre protein 'knob' domain tion. Antibodies specific for the fibre epitope have been to the recently identified coxsacki-adenovirus receptor. 5, 6 shown to neutralise virus infection 11 and making such Subsequent internalisation of the virus particle requires antibodies bifunctional should redirect binding to other a further interaction between the penton base proteins of receptors whilst leaving the potential for penton-integrin the viral capsid, and integrins on the surface of the cell. [7] [8] [9] binding intact. We therefore set out to explore this The cell membrane, with bound adenovirus, invaginates approach to targeting adenovirus gene delivery. to form a clathrin-coated vesicle and then an endocytic
The ability to engineer antibodies has been facilitated vesicle, following dissociation of the clathrin. The penton by expression of fragments in bacteria. Many different base proteins mediate disruption of the endosome and fragments including bispecific forms or fusion proteins the uncoated virus escapes into the cytosol where it may be produced in this way. Here we report the promigrates to the nuclear membrane. Finally, the viral core duction of a phage library from mice immunised with binds with the nuclear pore complexes and releases its recombinant adenoviral fibre. Single chain Fv antibody DNA into the nucleus. 10 Therefore, adenovirus infection fragments (scFv) specific to the fibre protein were selecas a whole is a form of receptor-mediated endocytosis.
ted and those which prevented adenovirus infection Initial entry into host cells, however is a unique two-step identified. One scFv was genetically linked to epidermal growth factor (EGF) 12, 13 to investigate adenoviral targeting via the EGF receptor (EGFR). The results showed scFvs were subcloned into a vector containing C-terminal Results histidine tags and purified using metal affinity chromatography. 18 Affinity measurements in solution were Soluble antigen production and immunisation determined using the Friguet ELISA technique. 19 The T4 phage fibritin is a trimer and can be expressed at a results obtained indicated that S11 had the higher affinity high level in bacteria. 14, 15 A fusion of the adenoviral knob of the two antibody fragments (S11 K d = 3 nm and VV16 protein with T4-fibritin was constructed (Figure 1 ). This K d = 12 nm). In addition, Western blots showed that S11 construct produced high-level expression of the fibreexpressed more soluble protein than VV16. Therefore the fibritin fusion, and the simple purification process 15 S11 scFv was chosen for detailed analysis. enabled production of large quantities (up to 100 mg/l) of purified protein. The fusion was active in that it could Viral inhibition prevent adenoviral infection in a virus neutralisation
The virus neutralisation assays were undertaken with assay at 30 g/ml (data not shown) and when serum varying concentrations of S11 and for different times. from mice immunised with the fibre-fibritin fusion proViral inhibition increased with increasing concentrations tein was assayed it was found to have high titres of adenof scFv (Figure 2a) . Neutralisation of infection reached ovirus neutralising antibodies (up to 1:2500).
up to 93% at 2.5 g/ml and 97% at 5 g/ml. Since the level of inhibition at 2.5 g/ml was near maximal, this Generation and screening of scFv repertoire concentration was taken as optimum for subsequent From the spleen of an immunised mouse a phage display assays. Time-course experiments on A431 cells assessed library of approximately 1 × 10 7 clones was made, as the duration of virus neutralisation by S11. The results described in the Materials and methods. Selection of the initial bacteriophage (phage 0) on solid phase antigen resulted in 3 × 10 3 clones after one round of selection (eluted bacteriophage termed phage 1). This increased markedly on the second round of selection to 6 × 10 4 clones (phage 2 eluted). Phage ELISA of polyclonal phage showed that both phage 1 and 2 bound strongly to the fusion protein. Soluble scFv was prepared for ELISA by infecting HB2151 with individual phage clones (from phage 2) and subsequently inducing protein expression. Of the clones tested, 75% (113 out of 150) bound to fibrefibritin fusion protein, with approximately 20% (31 out of 150) showing specificity for fibre (ie binding strongly to the fusion protein but weakly or not at all to T4 fibritin). When these fibre-specific clones were tested on a virus neutralisation assay, nine of them were shown to effectively inhibit viral infection.
Analysis of selected scFv clones
To analyse the diversity of these clones BstNI fingerprinting was undertaken as described. 16 This identified three different digestion patterns and consequently at least three different types of antibody fragment. VV16, V40 and S11 were chosen as examples of each of these digestion patterns and fully characterised. Western blots 17 of induced culture supernatants showed that V40 produced considerably more soluble protein than VV16 and S11 and yet was consistently less effective at inhibiting virus infection in neutralisation assays. This suggested either a low affinity or that a suboptimal epitope was recognised so it was not pursued further. Characterisation of the two remaining antibody fragments showed that they had different sequences, bound to overlapping epitopes (they competed for binding to fibre in ELISAs), and had reasonably high affinities. The indicated that at least 90% inhibition of viral infection was maintained for up to 24 h (Figure 2b ).
Construction and characterisation of scFv-EGF fusion
In order to target adenovirus binding to specific receptors, a bifunctional antibody was required. An EGF fusion with the S11 scFv was constructed (Figure 3a) and also a control EGF fusion with the B1.8 (anti-3-iodo-4-hydroxy-5-nitrophenacetyl(NIP)) scFv. 20 Both proteins (S11-EGF and B1.8-EGF) were found to be functional in terms of scFv binding to antigen, as judged by ELISA. In addition, Western blots showed clearly the increased size of the fusion protein (Figure 3b ). Flow cytometric analysis confirmed the retention of EGFR binding on A431 cells by the scFv-EGF construct (Figure 3c ).
Targeting adenoviral gene delivery
Preliminary testing of the adenobody approach used bac- fusion proteins were eluted with increasing salt concentrations and found largely in the 100 mm NaCl fraction.
Concentrations were determined by comparison with
The adenobody concentration was titrated in a virus targeting assay on A431 cells to determine the optimal known protein standards on SDS-PAGE and Western blots. The yield of protein was approximately 0.4-0.5 concentration for efficient gene delivery. This showed that adenobodies enhanced gene delivery at all conceng/ml of B1.8-EGF culture or 0.2-0.25 g/ml of S11-EGF culture.
trations tested (from 0.02 g/ml to 10 g/ml) but that the optimal concentration was 2.5 g/ml (Figure 4) . At penton interaction in viral entry. The two-step adenoviral binding mechanism revealed by Wickham et al, 7 showed higher concentrations the enhancement of infection began to decline, presumably due to competition of free that an RGD peptide could inhibit infection by the virus. The adenoviral penton base contains RGD motifs and and virus-bound adenobody for the EGFR. At the optimum concentration viral gene delivery was enhanced 16- blocking this interaction with cell surface integrins inhibits viral entry. Such peptide inhibition experiments fold ( Figure 4 ) and in other experiments at least ninefold, compared with the unmodified virus control. S11 at were used to determine if this mechanism was still required for entry of the adenobody-targeted virus. Pre-2.5 g/ml inhibited adenoviral infection of A431 cells by more than 93% giving an overall potential targeting ratio incubation of A431 cells with 2.0 mg/ml of GRGDSP at 4°C before adding recombinant adenovirus (10 6 of over 200. The control B1.8-EGF fusion at the same concentration (2.5 g/ml) had no effect on viral infection p.f.u./ml), reduced adenoviral infection by just over 40%. When the amount of peptide was increased to 3.0 mg/ml, (Figure 5b and c) .
Figure 3 Construction and characterisation of scFv-EGF fusion. (a) Diagrammatic representation of the scFv-EGF fusion construct in pUC119. Expression was driven from the upstream LacZ promotor. (b) Western blot of concentrated, induced culture supernatants. Protein is detected with a rabbit anti-Fv anti-serum. 17 Lane 1 shows S11 antibody fragment (MW approximately 27 kDa); lane 2 shows the S11-EGF fusion protein (MW approximately 32 kDa). The smaller bands of approximately 14 kDa represent proteolytic fragments which are the free V H and V K of the scFv. (c) Receptor binding activity of adenobody protein: flow cytometric analysis on A431 cells using scFv(B1-8)-EGF detected with an FITC-conjugated goat anti-murine lambda light chain antibody. Positive staining with scFv(B1-8)-EGF followed by FITC-conjugated anti-murine lambda antibody () is seen compared to controls with FITC-conjugated second layer antibody alone ( ).
To confirm that gene delivery required binding to the viral infection was reduced by approximately 70% (Figure 7a ). Ad5.LacZ + S11-EGF (at 2.5 g/ml) was also EGFR, competition experiments were performed ( Figure  5a ). Pre-incubating the cell monolayers with excess EGF added to cells pre-incubated with GRGDSP. By contrast, neither the 2.0 mg/ml nor the 3.0 mg/ml concentration (25 g/ml) blocked the EGFRs and a low incubation temperature (4°C) prevented internalisation of the recepof synthetic peptide had any effect on the level of targeted viral infection. In each experiment, adenoviral tartors. 21 The targeted infection was reduced 35-fold to a level approximately 70% lower than the positive control geting to untreated A431 cells resulted in about a ninefold increase over the normal Ad5.LacZ infection ( Figure  (Figure 5b and c) . EGF at a concentration of 25 g/ml had no effect on normal viral infection (Figure 5b and c) .
7b). This suggested that the penton-integrin interaction was bypassed using adenobodies to the EGFR. Effect of receptor number on viral targeting/enhancement
Discussion
To assess the effects of differing densities of EGFR on the target cells a number of other cell lines were examined.
Recombinant adenoviral vectors offer a number of Analysis of EJ and Hela cells by flow cytometry indicated advantages over retroviral vectors, particularly for in vivo that both cell lines expressed less EGFR than A431 cells gene delivery and cancer therapy. 22 They can be generwith EJ expressing more receptors than Hela ( Figure 6 ). ated to much higher titres, they can infect fully differenInhibition of viral infection by S11 was comparable for tiated tissues and are resistant to inactivation by human all three cell lines. Adenobody-mediated enhancement of complement. 22 Their wide host range is a disadvantage infection, however, was approximately four-fold on EJ and consequently, a simple and efficient method of tarcells. HeLa cells, with the lowest level of receptor, geting adenoviral infection to specific cells would be showed enhancement by 1.4-fold (Figure 5c ). The results valuable. By fusing EGF to an antifibre scFv we have indicated a decrease in adenobody-enhanced infection blocked the natural cell-binding site of the adenovirus when the number of target receptors is reduced.
whilst simultaneously supplying a binding alternative in the EGFR. The scFv-EGF fusion protein or 'adenobody' Method of targeted viral entry acts to link the recombinant virus to the new receptor. To assess the mechanism of adenobody targeting through Targeted infection could be competed out by prethe EGFR we examined the involvement of the integrin- fibre to add multiple lysines and have shown that this increases the viral infectivity across a broad range of cell The penton base proteins were left free to interact with cell surface integrins and initiate virion internalisation, as types, but infection is not targeted. The EGFR is overexpressed in a wide range of carcioccurs in natural adenoviral infection. 7 However, there are three methods by which the targeted adenovirus nomas and sarcomas, including glioblastomas, bladder tumours, advanced gastric tumours and cervical cancould gain entry to the host cell. The virus could be internalised as a complex with the EGF receptor; the cers. 32 The S11-EGF adenobody could therefore be a valuable tool for cancer gene therapy. Furthermore, the simadenovirus could bind to the EGFR but utilise its penton base proteins for internalisation by the usual pathway; or plicity of our system means that altering the target for adenoviral gene delivery involves merely exchanging the the virus could be initially targeted to the EGFR but may then dissociate from the adenobodies after a period of existing EGF for a new ligand. Alternatively the ligand could be replaced with a second scFv to produce a bitime and infect the host cell via the fibre receptor. If either of the last two routes were operating then blocking cell specific antibody fragment. Whether these bispecific fragments are diabodies, 33 CRAbs, 34 or simply fusion prosurface integrins with a synthetic RGD peptide would reduce virus infection. However, although pre-incubation teins, 35 they would enable the expansion of potential targeting protocols to include many other cell surface of A431 cells with the GRGDSP peptide reduced regular recombinant adenoviral infection as expected, 7 targeted proteins. In conclusion, the adenobody system has potential for increased efficiency and safety in a wide range of infection remained unaffected. This suggested that the virus-adenobody complex was internalised via the recepclinical gene therapy protocols. tor-mediated endocytic pathway of the EGFR. 13 By-passing the penton binding to ␣ v ␤ integrins in this way, could
Materials and methods prove advantageous for targeting some cells. For example, B and T lymphocytes are infected poorly by
Cell lines adenovirus due to their lack of the appropriate inte-A431, human squamous carcinoma cells, were obtained grins. 23 
from ECACC (Porton Down, UK) (No. 85120602). HeLa In utilising this route, viral gene delivery to A431 cells cells (human cervix carcinoma) were also obtained from was increased by around 10-fold (Figures 4, 5 and 6). This ECACC (No. 85060701). EJ cells are a human bladder carwas from a baseline of already efficient gene delivery and
cinoma cell line and were donated by F Morling from the represented a highly effective transduction. Experiments MRC Centre, Cambridge, UK. All cell lines were mainon a human osteosarcoma line (791T), which also marktained in Dulbecco's modified Eagle's medium (DMEM) edly overexpressed the EGFR, gave comparable results (Sigma, Poole, UK) with 1000 mg/l of glucose, 10% foetal to those achieved on A431 (data not shown). A high calf serum (FCS) and stabilised l-glutamine penicillinabundance of EGFR on target cells thus appears streptomycin solution (Sigma). important in the enhancement of gene delivery. Flow cytometric analyses showed that the expression of EGFR on A431 cells (3 × 10 6 EGFR/cell) 13 was higher than that Production of a soluble antigen DNA encoding the C-terminal 222 amino acid residues on EJ cells which in turn express more receptors than HeLa (75 000 EGFR/cell). 24 This reflected the targeting of the Ad5 fibre protein was amplified by PCR (25 cycles) from adenoviral DNA using the following primers: observed and illustrated its relation to receptor density. The high density of the overexpressed EGFR may also forward 5′-AGGTGCCATTACAGTAGCATGCAAA and back 5′-CACGTTGAAAGATATCACAACGATTC. explain the enhanced infectivity as the density is higher than that reported for the adenovirus receptor. 7, 25 The forward primer incorporated a SphI site and the back primer added an EcoRV site to the gene and, after There have been other reports of viral targeting. Methods of targeting retroviral vectors generally exhibit digestion of the DNA with these enzymes, the fragment was cloned into the plasmid pRR2. 15 Based on a pTZ19 a substantial loss of infectivity. 21, [26] [27] [28] [29] Recently, in a similar approach to the one described here, Douglas et al 30 expression vector (Pharmacia Biotech) containing a T7 promoter, the pRR2 plasmid expresses the entire length have shown that a Fab-folate conjugate can target an adenoviral vector to the high affinity folate receptor.
of the fibritin protein from bacteriophage T4 (486 amino acid residues) plus an additional polypeptide of 53 resiTheir demonstrated targeted infection was impressive but did not reach the level of native adenoviral infecdues (45 of which are from the pre-S2 region of hepatitis B virus) and contains SphI and NruI restriction sites tivity. Like the EGFR, folate receptors are overexpressed on a variety of tumour cells. However, they are (created by site-directed mutagenesis). Restriction of pRR2 with SphI and NruI enzymes completely eliminates internalised into caveolae which appear too small to accommodate an adenovirus particle. 30 Consequently, the 53 amino acid polypeptide insertion (Figure 1 ). E. coli BL21(DE3) or pLysS(DE3) were transformed with the Douglas et al suggested that folate targeted adenoviral infection was still mediated via the penton-integrin interpRR2 plasmid and the bacteria were grown up to 200 ml in 2 × TY-GLU-AMP at 37°C to an optical density (600 action which may explain the lower efficiency compared with our system. In the work described here, the infection nm) of 1.0. Expression of the fibre-fibritin fusion protein was induced by addition of 1 mm isopropyl-␤-d-thiogalefficiency of the adenovirus was not only retained when targeted, but was improved upon in all the three different actoside (IPTG) and incubation for 4 h, with shaking at 30°C. Cells were harvested by centrifugation for 10 min cell types examined. It is likely that the efficiency of targeting will be dependent upon a number of factors at 4000 g and then resuspended in 4 ml TE buffer + 0.4 mg/ml of lysosyme. The suspension was incubated on including the receptor density, their affinity and the route ice for 20 min, sonicated for 2 min (15 s on/15 s pause) washed 10 times with PBS/0.1% Tween 20 and then 10 times with PBS and bound bacteriophage were eluted by and then centrifuged for 10 min at 21 000 g. The supernatant was retrieved and a saturated solution of adding 1 ml of 100 mm triethylamine and incubating for 5 min with rotation. Eluted material was immediately ammonium sulphate was added to 25-30%, then incubated on ice for 1 h. The suspension was centrifuged for neutralised by adding 0.5 ml 1 m Tris (pH 7.4). Phage were stored at 4°C. 16, 37 Eluted phage (500 l) were used 10 min (21 000 g), and the pellet was dissolved in 3-4 ml of TE buffer before purification on hydroxyapatite (HAP) to infect 50 ml of logarithmically growing E. coli TG1 in 2 × TY medium and then were plated on to large column followed by ion exchange chromatography. 15 Protein was eluted by step gradient of NaCl (243 × 243 mm) plates of TYE-GLU-AMP. Plates were incubated overnight at 37°C. Phage were regenerated, in 50 mm Tris-HCl (pH 8.5) and the relevant fractions were dialysed against 50 mm Tris-HCl (pH 8.5). The precipitated and subjected to two further rounds of selection. Final selected phage were used to infect E. coli protein solution was concentrated and finally its purity checked by SDS-PAGE analysis.
HB2151 and protein expression was induced with IPTG.
16,37
Production of a phage display library Three mice were immunised by subcutaneous injection Screening of selected phage for anti-fibre scFv Induced culture supernatants of individual clones were with 100 g of fibre-fibritin fusion protein in complete Freund's adjuvant followed by a second subcutaneous screened with ELISA for specific binding to the fibre-fibritin protein. Ninety-six well ELISA plates (Falcon plates; injection with 100 g of fusion protein in incomplete Freund's adjuvant. Antisera of all three mice were tested Becton Dickinson) were coated overnight at 4°C with fusion protein (5 g/ml) or with pure fibritin protein for presence of adenovirus-inhibiting antibodies using a virus neutralisation assay (see below). Following an intraalone (5 g/ml), diluted in PBS. Plates were blocked with 3% MPBS for 1 h at 37°C and then washed three times venous boost with 20 g soluble fusion protein, the spleen of mouse 2 (which produced the highest antibody with PBS. Fifty microlitres of each supernatant were added to the wells, with equal volume of 3% titre) was removed, homogenised and total RNA extracted using an RNEasy total RNA kit (Qiagen, W SusMarvel/PBS/0.1% Tween-20 and incubated at room temperature for 1 h. Wells were washed three times with sex, UK). RNA was converted to cDNA using super reverse transcriptase (HT Biotechnology, Cambridge, PBS/0.1% Tween-20 and then three times with PBS. Antibody protein was detected with the anti-myc tag anti-UK) and the cDNA was then used as a template for a primary PCR in order to amplify out the heavy and body 9E10, 17 followed by anti-mouse Fc-HRP conjugated antibody (Sigma). The signal was developed with BM kappa light chain variable region genes (V H and V K ) (primers supplied by Cambridge Antibody Technology, blue POD substrate (Boehringer Mannheim, E Sussex, UK), stopped with 1 m sulphuric acid and the optical Melbourn, UK). The reaction was subjected to 25 cycles of 94°C (1.0 min), 60°C (1.0 min) and 74°C (1.0 min), then density read on a Softmax plate reader (Molecular Devices, Sunnyvale, CA, USA). Clones which were posiheld at 60°C for 5 mins and allowed to cool to room temperature. A secondary PCR, with 10 cycles of 94°C (1 tive for binding to the fusion protein but showed no reaction with the pure fibritin were considered fibre-specific min), 50°C (1 min) and 74°C (1 min), added restriction sites and complementary ends to the DNA fragments. A and were tested for their ability to block the adenoviral fibre receptor in a virus neutralisation assay. third PCR (assembly PCR) allowed the random joining of the V H and V K genes to form a single chain Fv 36 (10 cycles with no primers, 94°C (1 min), 55°C (1 min), 74°C
Characterisation of scFv The isolated scFv were subcloned from pHEN1 into a (1 min) followed by addition of outer primers and 15 further cycles of 94°C (1 min), 74°C (2 min). The scFv was pUC119 based expression vector containing the His 6 tail followed by a myc tag (pUC119-pelBpolyHisMyc). cloned as a Nco1/Not1 fragment into pHEN1 phagemid vector 37 and then electroporated into E. coli XL1-Blue Expressed protein was purified on NTA-agarose columns (Qiagen) following the method of Skerra et al. 18 The (Stratagene, Cambridge, UK). The transformed bacteria were plated on to large plates of TYE + 1% glucose + 100 affinities of the isolated clones were determined in solution as described by Friguet et al. 19 g/ml ampicillin + 30 g/ml tetracycline and incubated overnight at 37°C, to generate a phage library of approximately 10 7 different V H /V K combinations. The bacteria Virus neutralisation assay Induced culture supernatant (or purified protein) was were scraped from the plates into 15 ml of 2 × TY-GLU-AMP-TET medium to make a library stock. 37 Specific phage antibodies were selected by panning. Polystyrene sity, Canada). 3 The Ad5.LacZ/protein mixtures were then added to confluent monolayers of human cells in tubes (Falcon 2058; Becton Dickinson, Oxford, UK) were coated overnight at 4°C with 4 ml fibre-fibritin fusion 24-well plates (Nunc, Roskilde, Denmark) and incubated overnight at 37°C. Cells infected with the recombinant protein in PBS (10 g/ml). After washing four times with PBS, the tube was blocked with 4 ml 3% Marvel/PBS adenovirus, express the ␤-galactosidase gene and thus appear blue upon staining with the X-gal substrate. 38 In (MPBS) by incubating at 37°C for 2 h. The tube was washed again with PBS and then incubated at room temthe selection of fibre-specific antibody fragments it was therefore a lack of blue staining that indicated inhibition perature for 4 h with 100 l of bacteriophage stock made up to 1 ml in 3% MPBS + 0.5% Tween 20. The tube was of viral gene delivery.
Virus neutralisation: time course assay teins was achieved, as in the ELISA, by incubation first with goat anti-hEGF antibody (R&D Systems) and then A mixture of 10 6 p.f.u./ml of Ad5.LacZ and 2.5 g/ml of S11 scFv protein was incubated for 1 h at 37°C. This with rabbit anti-goat HRP conjugated antibody (Sigma). For detection of VV16 or S11 anti-fibre antibody fragmixture was added to confluent monolayers of A431 cells (as above). At each relevant time-point, the mixture was ment, the NC paper was incubated either with 9E10 antibody followed by anti-mouse Fc HRP conjugated antiremoved from the appropriate wells, the cells were washed with PBS and fresh DMEM (10% FCS) was body (Sigma) or with a rabbit anti-Fv antibody followed by sheep anti-rabbit HRP conjugated antibody (ICN, added. Incubation was continued overnight at 37°C. Cells were X-gal-stained after 24 h and infected cells were Buckinghamshire, UK). 17 In all cases antibodies were diluted in 3% BSA/PBS/0.1% Tween-20 and incubations counted.
were for 1 h at room temperature with gentle rocking. Blots were developed in 15 ml of 3′3′diaminobenzamide Production of EGF-scFv fusion proteins The EGF gene was amplified from a plasmid (gift from (Fast Dab Tabs; Sigma). F Morling) 28 by PCR (94°C for 1 min, 55°C for 1 min, 72°C for 1 min for 15 cycles) using Vent polymerase (New Virus targeting assay England Biolabs, Hertfordshire, UK). The gene was gel Ad5.LacZ recombinant adenovirus was mixed with scFvpurified and then cloned as a NotI/EcoRI fragment into EGF to a final concentration of 10 6 p.f.u. of virus per millipUC119-pelBpolyHisMyc at the 3′ end of the B1.8 (antilitre in DMEM + 10% FCS and then incubated at 37°C for NIP antibody) gene so replacing the C-terminal HisMyc 1 h. Protein/virus solution (0.5 ml) (overall multiplicity tag. The construct was expressed in E. coli TG1-R and of infection (MOI) approximately 3) was added to coninduced culture supernatants were tested for the presfluent monolayers of A431 cells in 24 well plates (Nunc) ence of the fusion protein by ELISA. Well plates were and incubated for 30 min. The cells were then washed coated with NIP conjugated bovine serum albumin (NIPwith PBS and the medium replaced with fresh DMEM + BSA), incubated with supernatant + 3% MPBS (as 10% FCS before continuing incubation at 37°C overnight. previously), and protein was detected with anti-human
To block the EGF receptors as a targeting control, pre-EGF polyclonal neutralising antibody (R&D Systems, cooled plates of cells were incubated with 25 g/ml of Oxfordshire, UK) followed by rabbit anti-goat HRP conhuman recombinant EGF (Sigma) for 15 min at 4°C. jugated antibody (Sigma). Positive clones were tested for Virus/protein mixture was then added and the cells were the presence of a functional EGF protein by flow cytoincubated for a further 30 min at 4°C. After the cells had metric analysis on A431 cells using an FITC-conjugated been washed and fresh medium added, incubation was goat anti-murine lambda light chain anti-sera (Southern continued at 37°C overnight. Adenoviral infection was Biotechnology, Birmingham, AL, USA). 39 The clone that detected by staining with X-gal 38 and quantified by counbound most efficiently to the cell surface EGF receptor ting blue stained cells as before. (clone 1) was taken, the B1.8 gene was removed by NcoI/NotI digestion and the anti-fibre scFv(S11) cloned 'RGD' peptide viral inhibition assay in its place. The new fusion protein was expressed in E. S11-EGF fusion protein and Ad5.LacZ were mixed to a coli TG1 and tested for fibre specificity by ELISA on fibrefinal concentration of 2.5 g/ml and 10 6 p.f.u./ml fibritin and pure fibritin protein. Positive binders were respectively and incubated for 1 h at 37°C. Monolayers used in virus targeting assays (see below) on A431 cells. of A431 cells in 24-well plates (Nunc) were precooled and Relative expression of the EGFR on different cell lines then incubated at 4°C for 45 min, with varying concenwas determined by flow cytometry using a mouse antitrations of the synthetic peptide GRGDSP. 7 The virus + EGFR (Ab-1; Oncogene Science) and a FITC-conjugated S11-EGF (0.5 ml) (or recombinant adenovirus alone) was sheep anti-mouse Fc antibody (Sigma) and standard added to cells which were then incubated for a further techniques. 39 30 min at 4°C. After half an hour, the cells were washed with PBS, the medium was replaced with fresh DMEM Purification of fusion proteins by ion exchange + 10% FCS, and incubation was continued overnight at chromatography 37°C. Adenoviral infection was determined by X-gal A column of DEAE Sephacel (Pharmacia) was prepared staining and then quantified by counting (as above). with a bed volume of 20 ml and equilibrated with 20 mm Tris-HCl (pH 7.4). A periplasmic preparation 18 from a 500
